



Universiteit
Leiden
The Netherlands

Inequity and spondyloarthritis: focus on the role of socioeconomic factors in disease

Nikiphorou, E.

Citation

Nikiphorou, E. (2023, January 26). *Inequity and spondyloarthritis: focus on the role of socioeconomic factors in disease*. Retrieved from <https://hdl.handle.net/1887/3512939>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3512939>

Note: To cite this publication please use the final published version (if applicable).

LIST OF PUBLICATIONS

1. Ramiro S, **Nikiphorou E**, Sepriano A, Ortolan A, Webers C, Baraliakos X, Landewé R, van den Bosch F, Boteva B, Bremander A, Carron P, Ciurea A, van Gaalen F, Géher P, Gensler LS, Hermann J, de Hooge M, Husakova M, Kiltz U, López-Medina C, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compán V, Nissen MJ, Pimentel-Santos FM, Poddubnyy D, Proft F, Rudwaleit M, Telkman M, Zhao SS, Ziade N, van der Heijde D. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. *Ann Rheum Dis* 2022. Accepted October 2022.
2. Webers C, Ortolan A, Sepriano A, Falzon L, Baraliakos X, Landewe R, Ramiro S, van der Heijde D, **Nikiphorou E**. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. *Ann Rheum Dis* 2022. Accepted October 2022.
3. Ortolan A, Webers C, Sepriano A, Falzon L, Baraliakos X, Landewe R, Ramiro S, van der Heijde D, **Nikiphorou E**. Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. *Ann Rheum Dis* 2022. Accepted October 2022.
4. Dey M, Nagy G, **Nikiphorou E**. Comorbidities and extra-articular manifestations in difficult-to-treat rheumatoid arthritis: different sides of the same coin? *Rheumatology (Oxford)* 2022. Accepted September 2022.
5. Yoshida A, Kim M, Kuwana M, Naveen R, Makol A, Sen P, Lilleker JB, Agarwal V, Kardes S, Day J, Milchert M, Joshi M, Gheita T, Salim B, Velikova T, Edgar Gracia-Ramos A, Parodis I, O'Callaghan AS, **Nikiphorou E**, Chatterjee T, Tan AL, Nune A, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L; COVAD Study Group. Impaired physical function in patients with idiopathic inflammatory myopathies: results from the multicentre COVAD patient-reported e-survey. *Rheumatology (Oxford)* 2022; keac441. doi: 10.1093/rheumatology/keac441. Online ahead of print.
6. Ovseiko PV, Gossec L, Andreoli L, Kiltz U, van Mens L, Hassan N, van der Leeden M, Siddle HJ, Alunno A, McInnes IB, Damjanov NS, Apparailly F, Ospelt C, van der Horst-Bruinsma IE, **Nikiphorou E**, Druce KL, Szekanecz Z, Sepriano A, Avcin T, Bertsias G, Schett G, Keenan AM, Pololi LH, Coates LC. Gender equity in academic rheumatology, current status and potential for improvement: a cross-sectional study to inform an EULAR task force. *RMD Open*. 2022 Aug;8(2):e002518. doi: 10.1136/rmdopen-2022-002518.
7. Marzo-Ortega H, Navarro-Compán V, Akar S, Kiltz U, Clark Z, **Nikiphorou E**. An improved understanding of sex and gender is crucial for precision rheumatology. *Clin Rheumatol*. 2022 Dec;41(12):3923-3924.
8. Fazal ZZ, Sen P, Joshi M, Ravichandran N, Lilleker JB, Agarwal V, Kardes S, Kim M, Day J, Makol A, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, **Nikiphorou E**, Tan AL, Chatterjee T, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Selva-O'Callaghan A, Nune A, Knitza J, Kuwana M, Gutiérrez CT, Caballero-Urbe CV, Dey D, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L; COVAD Study Group. COVAD survey 2 long-term outcomes: unmet need and protocol. *Rheumatol Int*. 2022 Aug 14;1-8.
9. Philippou E, **Nikiphorou E**. Gluten or no gluten for rheumatic diseases? *Joint Bone Spine*. 2022 Aug 12;89(6):105453.
10. Studenic P, Sekhon M, Carmona L, de Wit M, **Nikiphorou E**. Unmet need for patient involvement in rheumatology registries and observational studies: a mixed methods study. *RMD Open*. 2022 Aug;8(2):e002472.

11. Passos A, Louka M, Vryonidis C, Inglezakis A, Loizou C, **Nikiphorou E**, Psarelis S, Kaliviotis E. Red blood cell sedimentation rate measurements in a high aspect ratio microchannel. *Clin Hemorheol Microcirc.* 2022 Aug 20. doi: 10.3233/CH-221476.
12. Gwinnutt JM, Norton S, Hyrich KL, Lunt M, Combe B, Rincheval N, Ruysen-Witrand A, Fautrel B, McWilliams DF, Walsh DA, **Nikiphorou E**, Kiely PDW, Young A, Chipping JR, MacGregor A, Verstappen SMM. The influence of social support, financial status and lifestyle on the disparity between inflammation and disability in rheumatoid arthritis. *Arthritis Care Res* 2022. Accepted July 2022.
13. Studenic P, Stamm TA, Mosor E, Bini I, Caeyers N, Gossec L, Kouloumas M, **Nikiphorou E**, Olsder W, Padjen I, Ramiro S, Stones S, Wilhelmer TC, Alunno A. EULAR points to consider for including the perspective of young patients with inflammatory arthritis into patient-reported outcomes measures. *RMD Open.* 2022;8(2):e002576. doi: 10.1136/rmdopen-2022-002576.
14. Gil-Vila A, Naveen R, Selva-O'Callaghan A, Sen P, Nune A, Gaur PS, Gonzalez RA, Lilleker JB, Joshi M, Agarwal V, Kardes S, Kim M, Day J, Makol A, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, **Nikiphorou E**, Tan AL, Chatterjee T, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L; COVAD Study Group. COVID-19 Vaccination In Autoimmune Diseases (COVAD) Study: Vaccine Safety In Idiopathic Inflammatory Myopathies. *Muscle Nerve.* 2022 Oct;66(4):426-437.
15. Traboco L, Pandian H, **Nikiphorou E**, Gupta L. Designing Infographics: Visual Representations for Enhancing Education, Communication, and Scientific Research. *J Korean Med Sci.* 2022 Jul 11;37(27):e214. doi: 10.3346/jkms.2022.37.e214.PMID: 35818705
16. Marzo-Ortega H, Navarro-Compán V, Akar S, Kiltz U, Clark Z, **Nikiphorou E**. The impact of gender and sex on diagnosis, treatment outcomes and health-related quality of life in patients with axial spondyloarthritis. *Clin Rheumatol.* 2022 Nov;41(11):3573-3581.
17. Busby AD, Wason J, Pratt AC, Young A, Isaacs JD, **Nikiphorou E**. The role of comorbidities alongside patient and disease characteristics on long-term disease activity in RA using UK inception cohort data. *Rheumatology (Oxford)* 2022;2022 Nov 2;61(11):4297-4304.
18. Dey M, Nagy G, **Nikiphorou E**. Comorbidities or extra-articular manifestations - time to reconsider the terminology? *Rheumatology (Oxford)* 2022 Oct 6;61(10):3881-3883.
19. Sen P, R N, Nune A, Lilleker JB, Agarwal V, Kardes S, Kim M, Day J, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, O'Callaghan AS, **Nikiphorou E**, Chatterjee T, Tan AL, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L; COVAD Study Group. COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study. *Rheumatology (Oxford).* 2022;keac305. doi: 10.1093/rheumatology/keac305. Online ahead of print.
20. Gwinnutt JM, Norton S, Hyrich KL, Lunt M, Combe B, Rincheval N, Ruysen-Witrand A, Fautrel B, McWilliams DF, Walsh DA, **Nikiphorou E**, Kiely P, Young A, Chipping JR, MacGregor A, Verstappen SMM. Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis. *Rheumatology (Oxford)* 2022;keac137. doi: 10.1093/rheumatology/keac137. Online ahead of print.
21. Conway R, **Nikiphorou E**, Demetriou CA, Low C, Leamy K, Ryan JG, Kavanagh R, Fraser AD, Carey JJ, O'Connell P, Flood RM, Mullan RH, Kane DJ, Ambrose N, Stafford F, Robinson PC, Liew JW, Grainger R, McCarthy GM; COVID-19 Global Rheumatology Alliance. Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland: data from the COVID-19 Global Rheumatology Alliance registry. *Rheumatology (Oxford).* 2022 Jun 28;61(SI2):SI151-SI156.
22. Cutolo M, **Nikiphorou E**. Nutrition and Diet in Rheumatoid Arthritis. *Nutrients.* 2022 Feb 19;14(4):888. doi: 10.3390/nu14040888.

23. Caton E, Chaplin H, Carpenter L, Sweeney M, Tung HY, de Souza S, Galloway J, **Nikiphorou E**, Norton S. The impact of consecutive COVID-19 lockdowns in England on mental wellbeing in people with inflammatory arthritis. *BMC Rheumatol*. 2022 Jun 29;6(1):37.
24. Dey M, Busby A, Elwell H, Lempp H, Pratt A, Young A, Isaacs J, **Nikiphorou E**. Association between social deprivation and disease activity in rheumatoid arthritis: a systematic literature review. *RMD Open*. 2022 Apr;8(1):e002058. doi: 10.1136/rmdopen-2021-002058.
25. Metsios GS, Brodin N, Vlieland TPMV, Van den Ende CHM, Stavropoulos-Kalinoglou A, Fatouros I, van der Esch M, Fenton SAM, Tzika K, Moe RH, van Zanten JJCSV, Koutedakis Y, Swinnen TW, Veskoukis AS, Boström C, Kennedy N, **Nikiphorou E**, Fragoulis GE, Niedermann K, Kitis GD; IM-PACT-RMD Consortium. Position Statement on Exercise Dosage in Rheumatic and Musculoskeletal Diseases: The Fole of the IMPACT-RMD Toolkit. *Mediterr J Rheumatol*. 2021 Dec 27;32(4):378-385. doi: 10.31138/mjr.32.4.378. eCollection 2021 Dec.
26. Sweeney M, Carpenter L, de Souza S, Chaplin H, Tung H, Caton E, Galloway J, Cope A, Yates M, **Nikiphorou E**, Norton S. The impact of COVID-19 on clinical care, self-management and mental health of patients with inflammatory arthritis. *Rheumatol Adv Pract*. 2021 Dec 4;6(1):rkab095. doi: 10.1093/rap/rkab095. eCollection 2022.
27. Alunno A, Rivellese F, Lauper K, Aletaha D, Buch MH, Gossec L, Mandl P, Machado PM, Ospelt C, Molto A, Ramiro S, **Nikiphorou E**, Sepriano A. EMerging EULAR NETWORK (EMEUNET): a remarkable foundation for the future. *RMD Open*. 2021 Dec;7(3):e001962. doi: 10.1136/rmdopen-2021-001962.
28. **Nikiphorou E**, Boonen A, Fautrel B, et al. How do clinical and socioeconomic factors impact on work disability in early axial spondyloarthritis? Five-year data from the DESIR cohort. *Rheumatol (Oxford)*. 2022 May 5;61(5):2034-2042.
29. Conway R, **Nikiphorou E**, Demetriou CA, et al; COVID-19 Global Rheumatology Alliance. Predictors of hospitalization in patients with rheumatic disease and COVID-19 in Ireland: data from the COVID-19 global rheumatology alliance registry. *Rheumatol Adv Pract*. 2021;5(2):rkab031.
30. **Nikiphorou E**, Carvalho P, Boonen A, Fautrel B, Richette P, Machado PM, van der Heijde D, Landewe R, Ramiro S. Sick leave in early axial spondyloarthritis: the role of clinical and socioeconomic factors. Five-year data from the DESIR cohort. *RMD Open*. 2021;7(2):e001685. doi: 10.1136/rmdopen-2021-001685.
31. Sen P, Gupta L, Lilleker JB, Aggarwal V, Kardes S, Milchert M, Gheita T, Salim B, Velikova T, Garcia-Ramos AE, Parodis I, O'Callaghan AS, **Nikiphorou E**, et al; COVAD Study Group. COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. *Rheumatol Int*. 2021; 42(1):23-29.
32. Capelusnik D, Zhao SS, Boonen A, Ziade N, Medina CL, Dougados M, **Nikiphorou E**, Ramiro S. Individual and country-level socioeconomic factors and health outcomes in spondyloarthritis: analysis of the ASAS perSpA study. *Rheumatol (Oxford)* 2022 May 5;61(5):2043-2053.
33. Zhao SS, **Nikiphorou E**, Boonen A, Lopez-Medina C, Dougados M, Ramiro S. Association between individual and country-level socioeconomic factors and work participation in spondyloarthritis including psoriatic arthritis: analysis of the ASAS-perSpA study. *Semin Arthritis Rheum*. 2021;51(4):804-812.
34. **Nikiphorou E**, Jacklin H, Bosworth A, Jacklin C, Kiely P. Disease impact of rheumatoid arthritis in patients not treated with advanced therapies; survey findings from the National Rheumatoid Arthritis Society. *Rheumatology Advances in Practice* 2021;0:1-9.
35. Dey M, Parodis I, **Nikiphorou E**. Fatigue in Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Comparison of Mechanisms, Measures and Management. *J Clin Med*. 2021;10(16):3566.

36. Zhao SS, **Nikiphorou E**, Young A, Kiely PDW. Large joints are progressively involved in rheumatoid arthritis irrespective of rheumatoid factor status-results from the early rheumatoid arthritis study. *Rheumatol Int*. 2022 Apr;42(4):621-629.
37. Busby AD, Wason J, Pratt AC, Young A, Isaacs JD, **Nikiphorou E**. Predictors of poor function in RA based on two prospective UK inception cohorts. Do comorbidities matter? *Rheumatol (Oxford)*. 2021;keab598. doi: 10.1093/rheumatology/keab598.
38. Bhatia A, Gaur PS, Zimba O, Chatterjee T, **Nikiphorou E**, Gupta L. The untapped potential of Instagram to facilitate rheumatology academia. *Clin Rheumatol*. 2021;1-7.
39. Paolino S, Hysa E, Stoian SA, Gotelli E, Casabella A, Clini PV, Pacini G, Pizzorni C, Sulli A, **Nikiphorou E**, Smith V, Cuto M. Metabolic Profile and Bone Status in Post-Menopausal Women with Rheumatoid Arthritis: A Monocentric Retrospective Survey. *Nutrients*. 2021;13(9):3168.
40. Fragoulis GE, **Nikiphorou E**, McInnes IB, Siebert S. Does age matter in Psoriatic arthritis? A narrative review. *J Rheumatol*. 2022 Oct;49(10):1085-1091.
41. de la Torre-Aboki J, Uson J, Pitsillidou I, Vardanyan V, **Nikiphorou E**, et al. Intra-articular therapies: patient preferences and professional practices in European countries. *Rheumatol Int*. 2022 May;42(5):869-878.
42. Grivas A, Fragoulis G, Garantziotis P, Banos A, **Nikiphorou E**, Boumpas D. Unraveling the complexities of psoriatic arthritis by the use of -Omics and their relevance for clinical care. *Autoimmun Rev*;20(11):102949.
43. Nagy C, Roodenrijs NMT, Welsing PMJ, Kedves M, Hamar A, van der Goes MC, Kent A, Bakkers M, Pchelnikova P, Blaas E, Senolt L, Szekanecz Z, Choy EH, Dougados M, Jacobs JW, Geenen R, Bijlsma JW, Zink A, Aletaha D, Sch`oneveld L, van Riel P, Dumas S, Prior Y, **Nikiphorou E**, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. *Ann Rheum Dis*. 2022 Jan;81(1):20-33.
44. Caton E, Chaplin H, Carpenter L, Sweeney M, Tung HY, de Souza S, Galloway J, **Nikiphorou E**, Norton S. The impact of COVID-19 on self-management behaviours and healthcare access for people with inflammatory arthritis. *BMC Rheumatol*. 2021;5(1):58.
45. Lee SY, Ibrahim F, Tom BDM, **Nikiphorou E**, et al. Baseline predictors of remission, pain and fatigue in rheumatoid arthritis: the TITRATE trial. *Arthritis Res Ther*. 2021;23(1):278.
46. Van Onna M, Ramiro S, Haines C, Holland-Fischer M, da Silva JAP, Dudler J, Edwards CJ, Alunno A, **Nikiphorou E**, et al. EULAR portfolio for Rheumatology training: a EULAR School of Rheumatology initiative. *RMD Open*. 2021;7(2):e001684. doi: 10.1136/rmdopen-2021-001684.
47. Marques A, Santos E, **Nikiphorou E**, Bosworth A, Carmona L. Effectiveness of self-management interventions in inflammatory arthritis: a systematic review informing the 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. *RMD Open* 2021;7(2):e001647.
48. Uson J, Rodriguez-García S, Castellanos-Moreira R, O'Neill TW, Doherty M, Boesen M, Pandit H, Möller I, Vardanyan V, Terslev L, Kampen WU, D'Agostino MA, Berenbaum F, **Nikiphorou E**, Pitsillidou I, de la Torre-Aboki J, Carmona L, Naredo E, Rodriguez-García SC. EULAR Recommendations for intra-articular therapies. *Ann Rheum Dis* 2021;80(10):1299-1305.
49. Rodriguez-García S, Castellanos-Moreira R, Uson J, Naredo E, O'Neill TW, Doherty M, Boesen M, Pandit H, Möller I, Vardanyan V, Terslev L, Kampen WU, D'Agostino MA, Berenbaum F, **Nikiphorou E**, Pitsillidou I, de la Torre-Aboki J, Carmona L, Rodriguez-García SC. Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: An overview of systematic reviews. *RMD Open*. 2021;7(2):e001658.

50. **Nikiphorou E**, Santos EJJ, Marques A, Bohm P, Bijlsma JWJ, Daien CI, et al. 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. *Ann Rheum Dis*. 2021;80(10):1278-1285.
51. Boonen A, Putrik P, Marques ML, Alunno A, Abasolo L, Beaton D, Betteridge N, Bjørk M, Boers M, Boteva B, Fautrel B, Guillemin F, Mateus EF, **Nikiphorou E**, **Péntek M**, **Pimentel Santos F**, **Severens JL**, **Verstappen SMM**, **Walker-Bone K**, **Wallman JK**, **Ter Wee MM**, **Westhovens R**, **Ramiro S**. EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis. *Ann Rheum Dis*. 2021;80(9):1116-1123.
52. Scott DL, Ibrahim F, Hill H, Tom B, Prothero L, Baggott RR, Bosworth A, Galloway JB, Georgopoulou S, Martin N, Neatrou I, **Nikiphorou E**, et al. Intensive therapy for moderate established rheumatoid arthritis: the TITRATE research programme. Southampton (UK): NIHR Journals Library; 2021. PMID: 34406722.
53. Toupin-April K, Décarry S, de Wit M, Meara A, Barton JL, Fraenkel L, Li LC, Brooks P, Shea B, Stacey D, Légaré F, Lydiatt A, Hofstetter C, Proulx L, Christensen R, Voshaar M, Suarez-Almazor ME, Boonen A, Meade T, March L, Jull JE, Campbell W, Alten R, Morgan EM, Kelly A, Kaufman J, Hill S, Maxwell LJ, Guillemin F, Beaton D, El-Miedany Y, Mittoo S, Westrich Robertson T, Bartlett SJ, Singh JA, Mannion M, Nasef SI, de Souza S, Boel A, Adebajo A, Arnaud L, Gill TK, Moholt E, Burt J, Jayatilleke A, Hmamouchi I, Carrott D, Blanco FJ, Mather K, Maharaj A, Sharma S, Caso F, Fong C, Fernandez AP, Mackie S, **Nikiphorou E**, Jones A, Greer-Smith R, Sloan VS, Akpabio A, Strand V, Umaefulam V, Monti S, Melburn C, Abaza N, Schultz K, Stones S, Kiwalkar S, Srinivasalu H, Constien D, King LK, Tugwell P. Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. *Semin Arthritis Rheum* 2021;51(3):593-600.
54. Roodenrys NMT, van der Goes MC, Welsing PMJ, van Oorschot EPC, **Nikiphorou E**, Nijhof NC, Tekstra J, Lafeber FPJC, Jacobs JWJ, van Laar JM, Geenen R. Non-adherence in difficult-to-treat rheumatoid arthritis from the perspectives of patients and rheumatologists: a concept mapping study. *Rheumatol (Oxford)*. 2021;60(11):5105-5116.
55. **Nikiphorou E**, Ibrahim F, Scott D.L. Rheumatoid Arthritis Real-world Management Over 20 Years. *J Rheumatol*. 2021;48(7):960-962.
56. Chaplin H, Carpenter L, Raz A, **Nikiphorou E**, Lempp H, Norton S. Summarising current Refractory Disease definitions in Rheumatoid Arthritis and Polyarticular Juvenile Idiopathic Arthritis: Systematic review. *Rheumatol (Oxford)* 2021;60(8):3540-3552.
57. Dey M, Busby A, Elwell H, Pratt A, Young A, Isaacs J, **Nikiphorou E**. The use and context of the term “multimorbidity” in rheumatoid arthritis: a systematic literature review. *Rheumatol (Oxford)* 2021;60(7):3058-3071.
58. Reuter K, Deodhar A, Makri S, Zimmer M., Berenbaum F., **Nikiphorou E**. COVID-19 pandemic impact on people with rheumatic and musculoskeletal diseases: Insights from patient-generated health data on social media. *Rheumatol (Oxford)* 2021;60(SI):SI77-SI84.
59. **Nikiphorou E**, Alpizar-Rodríguez D., Gastelum-Strozzi A., Buch M., Peláez-Ballestas I. Syndemics & syndemogenesis in COVID-19 and rheumatic and musculoskeletal diseases: old challenges, new era. *Rheumatol (Oxford)* 2021;60(5):2040-2045.
60. Mosor E., Studenic P, Alunno A., Padjen I., Olsder W., Ramiro S., Bini I., Caeyers N., Gossec L., Kouloumas M., **Nikiphorou E**, Stones S., Willehelemer T., Stamm T. Young people's perspectives on patient-reported outcome measures in inflammatory arthritis: results of a multi-centre European qualitative study from a EULAR Task Force. *RMD Open* 2021;7(1):e001517.

61. Korendovych V, Fleischhammer J, Tampe B, **Nikiphorou E**, Vasko R, Müller GA, Korsten P. Severely destructive unilateral wrist arthritis as a rare variant of rheumatoid arthritis: analysis of clinical and imaging features. *Clin Exp Rheumatol* 2021;39(2):372-377.
62. Nagy G, Roodenrijs NM, Welsing PM, Kedves M, Hamar A, van der Goes MC, Kent A, Bakkers M, Blaas E, Senolt L, Szekanecz Z, Choy E, Dougados M, Jacobs JW, Geenen R, Bijlsma HW, Zink A, Aletaha D, Schoneveld L, van Riel P, Gutermann L, Prior Y, **Nikiphorou E**, Ferraccioli G, Schett G, Hyrich KL, Mueller-Ladner U, Buch MH, McInnes IB, van der Heijde D, van Laar JM. EULAR definition of difficult-to-treat rheumatoid arthritis. *Ann Rheum Dis* 2021; 80(1):31-35.
63. Dey M., Cutolo M., **Nikiphorou**. Beverages in Rheumatoid Arthritis: What to Prefer or to Avoid. *Nutrients*. 2020 Oct 15;12(10):E3155.
64. Zouboulis CC, Benhadou F, Byrd AS, Chandran NS, Giamarellos-Bourboulis EJ, Fabbrocini G, Frew JW, Fujita H, González-López MA, Guillem P, Gulliver WPF, Hamzavi I, Hayran Y, Hórvath B, Hüb S, Hunger RE, Ingram JR, Jemec GBE, Ju Q, Kimball AB, Kirby JS, Konstantinou MP, Lowes MA, MacLeod AS, Martorell A, Marzano AV, Matusiak Ł, Nassif A, **Nikiphorou E**, Nikolakis C, Nogueira da Costa A, Okun MM, Orenstein LAV, Pascual JC, Paus R, Perin B, Prens EP, Röhn TA, Szegedi A, Szepletowski JC, Tzellos T, Wang B, van der Zee HH. What causes hidradenitis suppurativa? - 15 years after. *Exp Dermatol*. 2020;29(12):1154-1170.
65. Conway R., **Nikiphorou E**. Treating interstitial lung disease in rheumatoid arthritis – the embers of hope. *Rheumatol (Oxford)* 2020;59(12):3589-3590.
66. Paalanen K., Puolakka K., **Nikiphorou E**, Hannonen P., Sokka T. Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study. *Rheumatol (Oxford)* 2021;60(5):2391-2395.
67. **Nikiphorou E**, Ramiro S. Work Disability in Axial Spondyloarthritis. *Curr Rheumatol Rep*. 2020;22(9):55.
68. **Nikiphorou E**, Ramiro S., Sepriano A., Ruysen Witrand A., Landewé R.B.M., van der Heijde D. Do smoking and socioeconomic factors influence imaging outcomes in axial spondyloarthritis? Five-year data from the DESIR cohort. *Arthritis Rheumatol* 2020;72(11):1855-1862.
69. Fragoulis G.E., Chatzidionysiou K., **Nikiphorou E**, Cope A., McInnes I.B. Damage accrual in rheumatoid arthritis: evaluating the joint and beyond. *Arthritis Rheumatol* 2020;72(12):1967-1970.
70. **Nikiphorou E**, Galloway J., Fragoulis G. Overview of IgG4-related aortitis and periaortitis. A decade since their first description. *Autoimmun Rev* 2020;19(12):102694.
71. Parperis K., Psarelis S., **Nikiphorou E**. Osteitis condensans ilii: current knowledge and diagnostic approach. *Rheumatol Int* 2020;40(7):1013-1019.
72. Najm A., Kostine M., Pauling J.D., Ferreira A.C., Stevens K., Smith E., Eguiluz-Gracia I., Studenic P., Rodriguez-Carrio J., Ramiro S., Alunno A., Richez C., **Nikiphorou E**, Sepriano A. Multidisciplinary collaboration among young specialists: results of an international survey by the emerging EULAR network and other young organisations. *RMD Open* 2020; 6(2):e001398.
73. Scott D., Ibrahim F., Hill H., Tom B., Prothero L., Baggott R.R., Bosworth A., Galloway J.B., Georgopoulou S., Martin N., Neatrou I., **Nikiphorou E**, Sturt J., Wailoo A., Williams F.M., Williams R., Lempp H. The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial. *Semin Arthritis Rheum*. 2020;50(5):1182-1190.
74. Sivera F, Alunno A, Najm A, Avcin T, Baraliakos X, Bijlsma JW, Badreh S, Burmester G, Cikes N, Da Silva JA, Damjanov N, Dougados M, Dudler J, Edwards CJ, Iagnocco A, Lioté F, **Nikiphorou E**, van Onna M, Stones SR, Vassilopoulos D, Haines C, Ramiro S. 2019 EULAR points to consider for the assessment of competences in rheumatology specialty training. *Ann Rheum Dis* 2021;80(1):65-70.

75. Metsios GS, Fenton SA, Moe HR, van der Esch M, van Zanten JV, Koutedakis Y, Vitalis P, Kennedy N, Brodin NC, Tzika A, Boström C, Swinnen TW, Jester R, Schneider KN, **Nikiphorou E**, Fragoulis GE, Vlieland TPMV, Van den Ende C, Kitas GD; IMPACT-RMD Consortium.. Implementation of Physical Activity into routine Clinical practice in Rheumatic Musculoskeletal Disease: The IMPACT-RMD study protocol and rationale. *Mediterr J Rheumatol*. 2020;30(4):231-236.
76. **Nikiphorou E.**, de Lusignan S., Mallen C., Khavandi K., Bedarida G., Buckley C.D., Galloway J., Raza K. Cardiovascular risk factors and outcomes in early rheumatoid arthritis: a population-based study. *Heart* 2020;106(20):1566-1572.
77. Rodriguez-Carrio J., Putrik P., Gwinnutt J., Sepriano A., Alunno A., Ramiro S., Leipe J., **Nikiphorou E.**, on behalf of the EMEUNET Working Group. Mentoring for post-doctoral researchers in rheumatology: The Emerging EULAR Network (EMEUNET) Post-Doc Mentoring Program. *RMD Open* 2020;6(1):e001139.
78. Carpenter L., **Nikiphorou E.**, Kiely P.D.W., Walsh D.A., Young A., Norton S. Secular changes in the progression of clinical markers and patient-reported outcomes in early rheumatoid arthritis. *Rheumatology (Oxford)* 2020; *epub ahead of print*.
79. Philippou E., Petersson S.D., Rodomar C., **Nikiphorou E.** Rheumatoid arthritis and dietary interventions: systematic review of clinical trials. *Nutr Rev* 2019; *epub ahead of print*.
80. Fragoulis GE, **Nikiphorou E**, Larsen J, Korsten P, Conway R. Methotrexate-Associated Pneumonitis and Rheumatoid Arthritis-Interstitial Lung Disease: Current Concepts for the Diagnosis and Treatment. *Front Med (Lausanne)*. 2019 Oct 23;6:238.
81. Metsios G.S., Moe R.H., van der Esch M., Veldhuijzen van Zanten J.J.C.S., Fenton S.A.M., Koutedakis Y., Vitalis P., Kennedy N., Brodin N., Bostrom C., Swinnen T.W., Tzika K., Niedermann K., **Nikiphorou E.**, Fragoulis G.E., Vlieland T.P.V.M., Van den Ende C.H.M., Kitas G.D. The IMPACT-RMD Consortium. The effects of exercise on cardiovascular disease risk factors and cardiovascular physiology in rheumatoid arthritis. *Rheumatol Int*. 2020 Mar;40(3):347-357.
82. Constantinou C.A., Fragoulis G.E., **Nikiphorou E.** Hidradenitis suppurativa: Infection, autoimmunity or both? *Therapeutic Advances in Musculoskeletal Disease* 2019; 11:1759720X19895488.
83. **Nikiphorou E.**, Norton S., Carpenter L., Walsh D., Creamer P., Dixey J., Young A., Kiely P. on behalf of ERAS and ERAN. Remission versus low disease activity: Function, Quality Of Life and Structural outcomes in the early Rheumatoid Arthritis Study and Network. *Rheumatology (Oxford)* 2020;59(6):1272-1280.
84. **Nikiphorou E.**, Baraliakos X. Treat to target in axial spondyloarthritis. *Rheum Dis Clin North Am* 2019;45(4):519-535.
85. Najm A., Lempp H., Gossec L., Berenbaum F., **Nikiphorou E.** Needs, experiences and views of people with rheumatic and musculoskeletal diseases on self-management mobile health apps: a mixed methods study. *JMIR MHealth UHealth* 2020;8(4):e14351.
86. Najm A., Gossec L., Benoist D., Weill C., Berenbaum F., **Nikiphorou E.** Mobile health Applications for self-management in rheumatic and musculoskeletal diseases: a systematic literature review. *JMIR* 2019; 26:7(11):e14730.
87. Najm A., **Nikiphorou E.**, Kostine M. EULAR Points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. *RMD Open* 2019;13:5(2):e001014.
88. Edelaar L, **Nikiphorou E**, Fragoulis GE, et al. 2019 EULAR recommendations for the generic core competences of health professionals in rheumatology. *Ann Rheum Dis* 2020;79(1):53-60.
89. Carpenter L., Barnett P., Mahendran E., **Nikiphorou E.**, et al. Secular changes in functional disability, pain, fatigue and mental well-being in early rheumatoid arthritis. A longitudinal meta-analysis. *Semin Arthritis Rheum*. 2020;50(2):209-219.

90. **Nikiphorou E.**, de Lusignan S., Mallen C., Khavandi K., Roberts J., Buckley C., Galloway J., Raza K. Haematological abnormalities in new onset rheumatoid arthritis and risk of common infections: a population-based study. *Rheumatology (Oxford)* 2020;59(5):997-1005.
91. **Nikiphorou E.**, Lempp H., Kohrt B. Treatment failure in Inflammatory Arthritis: time to think about Syndemics? *Rheumatology (Oxford)* 2019;58(9):1526-1533.
92. **Nikiphorou E.**, de Lusignan S., Mallen C., Roberts J., Khavandi K., Bedarida G., Buckley C., Galloway J., Raza K. Prognostic value of comorbidity indices and lung diseases in early rheumatoid arthritis: a UK population-based study. *Rheumatology (Oxford)* 2019;59(6):1296-1305.
93. Fragoulis G., Conway R., **Nikiphorou E.** Methotrexate and Interstitial Lung Disease: controversies and questions. A narrative review of the literature. *Rheumatology (Oxford)* 2019;58(11):1900-1906.
94. Fragoulis G., Panayotidis I., **Nikiphorou E.** Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment. *Curr Vasc Pharmacol.* 2020;18(5):431-446.
95. Fragoulis G., Constantinou C., Sipsas N., Hyrich K., **Nikiphorou E.** Tuberculosis in Inflammatory arthritis. Are biologics the only culprits? *The Lancet Rheumatology* 2019; 1: 3, E138-E140.
96. Yates M., Bechman K., Norton S., **Nikiphorou E.**, Galloway J. Centre Effects and case-mix in early rheumatoid arthritis observational cohorts: a narrative review. *Rheumatology (Oxford)* 2019;58(11):1991-1999.
97. Kiely P., Busby A.D., **Nikiphorou E.**, Sullivan K., Walsh D.A., Creamer P., et al. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. *BMJ Open* 2019; 9(5):e028466.
98. Bechman K., Clarke B., Rutherford A., Yates M., **Nikiphorou E.**, Molokhial M., et al. Polypharmacy predicts treatment response and serious adverse events in patients with rheumatoid arthritis; results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. *Rheumatology (Oxford)* 2019; 58(10):1767-1776.
99. Philippou E., **Nikiphorou E.** Are we really what we eat? Nutrition and its role in the onset of rheumatoid arthritis. *Autoimmun Rev* 2018;17(11):1074-1077.
100. Carpenter L., Norton S., **Nikiphorou E.**, Kiely P., Walsh D.A., Dixey J., Young A. Validation of methods for converting the original Disease Activity Score (DAS) to the DAS28. *Rheumatol Int* 2018;38(12):2297-2305
101. Petersson S., Philippou E., Rodomar C., Nikiphorou E. The Mediterranean diet, fish oil supplements and Rheumatoid arthritis outcomes: evidence from clinical trials. *Autoimmun Rev* 2018;17(11):1105-1114.
102. Psarelis S., Panayotidis I., **Nikiphorou E.** Osteosclerotic Bone Lesions of the Skull. *Arthritis Rheumatol* 2018;70(11):1819.
103. Michaud M., Panayotidis I., Psarelis S., Nakos G., **Nikiphorou E.** Elevated CA-125 in IgG4 mesenteritis: a red herring or a disease biomarker? Case report and literature review. *Rheumatol Int* 2018;39(7):1285-1289.
104. **Nikiphorou E.**, Fragoulis G.E. Inflammation, obesity and rheumatic disease: from pathophysiological links to disease outcomes. A narrative review. *Ther Adv Musculoskelet Dis* 2018; 27:10(8):157-167.
105. **Nikiphorou E.**, Nurmohamed M.T., Szekanecz Z. Editorial: Comorbidity Burden in Rheumatic Diseases. *Front Med (Lausanne)* 2018;5:197.
106. **Nikiphorou E.**, Hannonen P., Asikainen J., Borodina J., Kokko A., Paalanen K., Rannio T., Sokka T. Survival and safety of infliximab bio-original and infliximab biosimilar (CT-P13) in usual rheumatology care. *Clin Exp Rheumatol* 2019;37(1):55-59.

107. Korsten P., Tampe B., Konig M.F., **Nikiphorou E.** Sarcoidosis and autoimmune diseases: differences, similarities and overlaps. *Curr Opin Pulm Med* 2018; 24(5):504-512.
108. **Nikiphorou E.**, Aletaha D., Bukhari M. Are we failing patients in our assessment of treatment failure? Editorial. *Rheumatol (Oxford)* 2019;58(4):561-562.
109. Rodriguez-Carrio J., Mozo L., Lopez P., **Nikiphorou E.**, Suarez A. Anti-High-Density Lipoprotein Antibodies and Antioxidant Dysfunction in Immune-Driven Diseases. *Frontiers in Medicine (Rheumatology)* 2018;5:114.
110. Rodriguez-Carrio J., Putrik P., Sepriano A., Molto A., **Nikiphorou E.**, Gossec L., Kvien T.K., Ramiro S., on behalf of the EMEUNET Working Group. Improving the peer review skills of young rheumatologists and researchers in rheumatology: the EMEUNET Peer Review Mentoring Program. *Viewpoint. RMD Open* 2018;4(1):e000619.
111. Cutolo M., **Nikiphorou E.** Don't neglect nutrition in rheumatoid arthritis! Editorial. *RMD Open* 2018;4:e000591.
112. Molto A., **Nikiphorou E.** Comorbidities in Spondyloarthritis. *Front Med (Lausanne)* 2018;5:62.
113. Twigg S., **Nikiphorou E.**, Nam J.L., Hunt L., Mankia K., Pentony P.E., Freeston J.E., Tan A.L., Emery P. Comorbidities in anti-CCP positive at-risk individuals do not differ from those patients with early inflammatory arthritis. *Front Med (Lausanne)* 2018;5:35.
114. **Nikiphorou E.**, Norton S., Young A., Dixey J., Walsh D., Kiely P. The Association of Obesity with Disease Activity, Functional Ability and Quality of Life In Early Rheumatoid Arthritis. *Rheumatology (Oxford)* 2018;57(7):1194-1202.
115. Kiely P., **Nikiphorou E.** Management of rheumatoid arthritis, *Medicine* 2018; doi.org/10.1016/j.mpmed.2018.01.006.
116. Soulaïdopoulos S., **Nikiphorou E.**, Dimitroulas T., Kitas G.D. The role of statins in disease modification and cardiovascular risk in rheumatoid arthritis. *Front Med (Lausanne)* 2018;5:24.
117. **Nikiphorou E.**, Berenbaum F. Patient-physician interaction on Social Media: The Physician's Point of View. *EMJ Innovations* 2018;2(1):40-42.
118. Radner H., Chatzidionysiou K., **Nikiphorou E.**, Gossec L., Hyrich K.L., Zabalan C., van Eijk-Hustings Y., Williamson P.R., Balanescu A., Burmester G.R., Carmona L., Dougados M., Finckh A., Haugeberg G., Hetland M.L., Oliver S., Porter D., Raza K., Ryan P., Santos M.J., van der Helm-van Mil A., van Riel P., von Krause G., Zavada J., Dixon W.G., Askling J. **2017 EULAR recommendations** for a core data set to support observational research and clinical care in rheumatoid arthritis. *Ann Rheum Dis.* 2018 Jan 4. pii: annrheumdis-2017-212256. doi: 10.1136/annrheumdis-2017-212256.
119. **Nikiphorou E.**, van der Heijde D., Norton S., Landewe R., Molto A., Dougados M., van den Bosch F., Ramiro S. Inequity in biologic DMARD prescription for Spondyloarthritis across the globe: results from the ASAS COMOSPA study. *Ann Rheum Dis.* 2017 Dec 8. pii: annrheumdis-2017-212457. doi: 10.1136/annrheumdis-2017-212457.
120. **Nikiphorou E.**, Studenic P., Alunno A., Canavan M., Jani M., Berenbaum F. 'Twitterland': a brave new world? *Ann Rheum Dis* 2017;77(8):1245-46.
121. **Nikiphorou E.**, Ramiro S., van der Heijde D., Norton S., Molto A., Dougados M., van den Bosch F., Landewe R. Comorbidities in Spondyloarthritis associated with poor function, work disability and quality of life: results from the ASAS-COMOSPA study. *Arthritis Care Res* 2018;70(8):1257-1262.
122. **Nikiphorou E.**, Uksila J., Sokka T. A cross-sectional study of vitamin D levels in a large cohort of patients with rheumatic diseases. *Clin Rheum* 2018;37(3):803-810.

123. Alunno A., Studenic P., **Nikiphorou E.**, Balazova P., van Nieuwkoop L., Ramiro S., Carubbi F., Richez C., Caeyers N., Kouloumas M. Person-focused care for young people with rheumatic and musculoskeletal diseases: a young rheumatologists and EULAR Young PARE perspective. *RMD* 2017 3(2):e000514.
124. **Nikiphorou E.**, Buch M.H., Hyrich K.L. Biologic registers in rheumatoid arthritis: methodological aspects, current role and future applications. *Nature Rev Rheum.* 2017;13(8):503-510.
125. **Nikiphorou E.**, Alunno A., Carmona L., Kouloumas M., Bijlsma H., Cutolo M. Patient-physician collaboration in rheumatology: a necessity. *RMD Open* 2017;18;3(1):e000499.
126. Khan N.A., Spencer H.J., **Nikiphorou E.**, Naranjo A., Alten R., Chirieac R.M., Drosos A.A., Géher P., Inanc N., Kerzberg E., Ancuta C.M., Müller R., Ørnbjerg L., Sokka T. Intercentre variance in patient reported outcomes is lower than physician and laboratory assessed measures of rheumatoid arthritis activity: Results from a cross-sectional multinational study. *Rheumatology (Oxford)* 2017; 56(8):1395-1400.
127. **Nikiphorou E.**, Neocleous V., Phylactou L.A., Psarelis S. Successful use of tocilizumab in two cases of severe autoinflammatory disease with a single copy of the Mediterranean fever gene. *Rheumatol (Oxford)* 2017; 56(9):1627-1628.
128. **Nikiphorou E.**, Mackie S.L., Kirwan J., Boers M., Isaacs J., Morgan A.W., Young A. Achieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis. *Rheumatology (Oxford)* 2017;56(4):550-555.
129. **Nikiphorou E.**, Galloway J., van Riel P.L., Ostor A., Haugeberg G., Gogus F., Kauppi M., Yazici Y., Sokka-Isler T. The Spectrum of Early RA Practice Across the Globe: Results from a Multinational Cross Sectional Survey. *Clin Exp Rheumatol* 2017;35(3):477-483.
130. Carpenter L., Norton S., **Nikiphorou E.**, Jayakumar K., McWilliams D.F., Rennie K.L., Dixey J., Kiely P., Walsh D.A., And Young A On Behalf Of ERAS & ERAN. Reductions in radiographic progression in early RA over 25-years: changing contribution from seropositivity in 2 multi-centre UK inception cohorts. *Arthritis Care Res* 2017;69(12):1809-1817.
131. **Nikiphorou E.**, Carpenter L., Norton S., Morris S., MacGregor A., Dixey J., Williams P., Kiely P., Walsh D.A., Young A. Can rheumatologists predict eventual need for orthopaedic intervention in patients with Rheumatoid Arthritis? Results of a systematic review and analysis of two UK inception cohorts. *Curr Rheum Reports* 2017; 19(3):12.
132. Jani M., **Nikiphorou E.**, Croft A., Bukhari M. Building the future of rheumatology: the role of national and international networks. Editorial. *Rheumatology (Oxford)* 2018;57(3):405-407.
133. Brown G., Kyei-Mensah A., Lachmann H.J., **Nikiphorou E.** A baffling case of severe systemic inflammation. Putting the pieces together: Genes, environment and triggers. *Rheumatol (Oxford)* 2017; 1;56(5):853-854.
134. **Nikiphorou E.**, Studenic P., Ammitzbøll C.G., Canavan M., Jani M., Ospelt C., Berenbaum F on behalf of EMEUNET. Social media use among young rheumatologists and basic scientists: results of an international survey by the Emerging EULAR Network (EMEUNET). *Ann Rheum Dis.* 2016; 76(4):712-715.
135. **Nikiphorou E.**, Radner H., Chatzidionysiou K., Desthieux C., Zabalan C., van Eijk-Hustings Y., Dixon W.G., Hyrich K.L., Askling J., Gossec L. Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. *Arthritis Res Ther.* 2016 Oct 28; 18(1):251. Review.
136. **Nikiphorou E.**, Norton S., Carpenter L., Dixey J., Walsh D.A., Kiely P., Young A. on behalf of ERAS & ERAN. Secular changes in clinical features at presentation of rheumatoid arthritis: Increase in comorbidity but improved inflammatory states. *Arthritis Care Res* 2017; 69(1):21-27.
137. Psarelis S., **Nikiphorou E.** Coexistence of systemic lupus erythematosus, tuberous sclerosis and aggressive natural killer-cell leukaemia: coincidence or correlated? *Lupus* 2017; 26(1):107-108.

138. Castrejon I., **Nikiphorou E.**, Jain R., Huang A., Block J.A., Pincus T. Fatigue and factors related to fatigue in rheumatic disease: a cross-sectional analysis from routine care on a Multidimensional Health Assessment Questionnaire (MDHAQ). *Clin Exp Rheumatol.* 2016; 34(5):901-909.
139. Väre P., **Nikiphorou E.**, Hannonen P., Sokka T. Delivering a one-stop, integrated, and patient-centered service for patients with rheumatic diseases. *SAGE Open Medicine* 2016; 6:1-7.
140. **Nikiphorou E.**, Sjöwall C., Hannonen P., Rannio T., Sokka T. Long-term outcomes of destructive seronegative (rheumatoid) arthritis - description of four clinical cases. *BMC Musculoskelet Disord.* 2016; 17(1):246.
141. Asikainen J., **Nikiphorou E.**, Kaarela K., Lindqvist E., Hakkinen A., Kautiainen H., Hannonen P., Rannio T., Sokka T. Is long-term radiographic joint damage different between men and women? Prospective longitudinal data analysis of four early RA cohorts with greater than 15 years follow-up. *Clin Exp Rheumatol.* 2016 Apr 28. [Epub ahead of print]
142. **Nikiphorou E.**, Norton S., Young A., Carpenter L., Dixey J., Walsh D.A., Kiely P; ERAS and ERAN. Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds. *Ann Rheum Dis.* 2016 75(12):2080-2086.
143. Carpenter L., **Nikiphorou E.**, Sharpe R., Norton S., Rennie K., Bunn F., Scott D., Dixey J., Young A. Have radiographic progression rates in early rheumatoid arthritis changed? A systematic review and meta-analysis of long-term cohorts. *Rheumatol (Oxford).* 2016 Mar 8. [Epub ahead of print]
144. **Nikiphorou E.**, Kautiainen H., Hannonen P., Asikainen J., Kokko A., Rannio T., Sokka T. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. *Expert Opin Biol Ther* 2015; 15(12):1677-83.
145. **Nikiphorou E.**, Rannio T., Sokka T. Rheumatoid arthritis in the 21st century: treatment patterns and disease activity states. Editorial. *J Rheumatol* 2015; 42(9):1542-4.
146. **Nikiphorou E.**, Young A., MacGregor A.J., Dixey J., Walsh D., Williams P., Kiely P., Morris S. Can standard clinical and laboratory disease markers and patient characteristics predict the length of stay for orthopaedic surgery in RA patients up to 25 years later? *J Rheumatol* 2015; 42(5):778-85.
147. **Nikiphorou E.**, Davies C., Mugford M., Davies C., Cooper N., Brooksby A., Bunn D., Symmons D., MacGregor A. The direct health costs of inflammatory polyarthritis ten years after disease-onset: results from the Norfolk Arthritis Register. *J Rheumatol* 2015; 42(5):794-8.
148. Corsava S, Psarelis S, **Nikiphorou E.** Giant Cell Arteritis of the Lower Limb Presenting as Peripheral Arterial Disease and Mantle Cell Lymphoma Two Years Later. *Clin Med Rev Case Rep* 2015; 2:034.
149. **Nikiphorou E.**, Konan S, MacGregor A.J, Haddad F., Young A. Editorial: The surgical treatment of rheumatoid arthritis: a new era? *Bone Joint J.* 2014;96-B (10):1287-1289.
150. **Nikiphorou E.**, Hall F. First report of improvement of coeliac disease in a patient with Sjogren's syndrome treated with rituximab. *Rheumatol (Oxford).* 2014 Oct; 53(10):1906-7.
151. **Nikiphorou E.**, Negoescu A., Fitzpatrick JD, Goudie C., Badcock A., Ostor AJK., Malaviya A. Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort. *Clin Rheumatol.* 2014; 33(5):609-14.
152. **Nikiphorou E.**, Carpenter L., Morris S., MacGregor A.J., Dixey J., Kiely P., James D., Walsh D., Norton S., Young A. Hand and foot surgery rates in RA have declined from 1986-2011, but large joint replacements remain unchanged. Results from two UK inception cohorts. *Arthritis Rheumatol.* 2014; 66 (5): 1081-9.

153. Carpenter L., **Nikiphorou E.**, and Young A. Importance of registries in informing clinical practice for arthritis. *Clinical Practice* 2013; 10, 723–736.
154. Ismajli M., **Nikiphorou E.**, Young A. An unusual case of childhood dermatomyositis recurring in adulthood half a century later. *BMJ Case Rep.* 2013; doi: 10.1136/bcr-2013-200008.
155. Norton S., Koduri G., **Nikiphorou E.**, Dixey J., Williams P., Young A. A study of baseline prevalence and cumulative incidence of co-morbidity and extra-articular manifestations in RA, and their impact on outcome. *Rheumatology (Oxford)* 2013; 52:99–110.
156. **Nikiphorou E.**, Guh D., Bansback N., Zhang W., Dixey J., Williams P., Young A. Work disability rates in RA. Results from an inception cohort with 24 years follow up. *Rheumatol (Oxford)* 2012; 51(2):385–392.
157. **Nikiphorou E.**, Mukhtyar C. Management of Antineutrophil Cytoplasmic Antibody associated vasculitis. *Current Immunology Reviews* 2011; 7(4):429–34.
158. **Nikiphorou E.**, Kerrigan N., Mills K., and Merry P. Rheumatologists: Inflammation doctors of the future. *Rheumatology (Oxford)* 2010; 49:607–8.
159. **Nikiphorou E.**, Young A. RA: Overview of recommended diagnosis and drug treatment. *Prescriber* 2010; 21:18–33.
160. **Nikiphorou E.**, Pyne D. Interpretation of C-reactive protein values in systemic lupus erythematosus. *Grand Rounds* 2009; 9:1–2.

CURRICULUM VITAE

Elena Nikiphorou was born on the 22nd of November 1979, in Nicosia, Cyprus. Supported by a scholarship, she moved to the UK to study medicine at University College London (University of London). She obtained her MBBS in Medicine in 2004, together with an Intercollegiate BSc in Physiology (2002), the latter supported by two awards and leading to a First-Class Honors degree. She undertook her rheumatology training in the East of England and additionally completed a Postgraduate Certificate in Medical Education at The University of Dundee, before returning to London. During her clinical training, Elena also took time 'out of programme' to complete a research degree in the UK, an MD (Res), followed by scientific fellowships in Finland (supported by EULAR) and Chicago (supported by The Royal Society of Medicine), further developing her research skills. These exposures and collaborations with senior colleagues in the field, were crucial in consolidating Elena's desire to pursue a clinical academic career, leading also to several awards and the undertaking of this thesis at Leiden University Medical Center. She is currently a Consultant Rheumatologist at King's College Hospital and in parallel, holds an Adjunct Senior Lecturer position and the Portfolio Assessment Lead position for the MBBS programme at King's College London.

ACKNOWLEDGEMENTS

This is the moment to put in writing breathings from the heart. It's not an easy task; so much is held in the heart, no words are strong enough.

I wish to start by thanking my incredible promotor and mentor, Professor Désirée van der Heijde. An admirable woman for whom I have intense and unconditional admiration, love, and respect. Désirée, next to you I have 'grown'; you have inspired and touched my life in the most extraordinary way.

Professor Robert Landewé, my second promotor. Thank you for believing in me, for your guidance and support. Thank you for instilling enthusiasm for research and for stimulating my inquisitive thinking.

This Dutch family would not have been the same without a truly special person to me, my co-promotor and dearest of friends, Dr Sofia Ramiro. Sofia, a beautiful life is a collection of unforgettable moments, of which the two of us have shared plenty.

I am endlessly honoured that I have completed this work with inspirational people by my side, whose work ethos and infectious enthusiasm for what they do, are breath-taking. I am truly humbled to have worked closely with Professor Annelies Boonen, whose wisdom, kind, and humbling nature have been inspirational. I wish to extend my thanks also to Professor Bruno Fautrel, Professor Filip Van den Bosch and my dear friends Dr Alexandre Sepriano and Dr Anna Molto, with whom I have worked closely as part of this thesis. I also wish to thank my two paranympths, Dr Féline Kroon and Dr Casper Webers for their valued friendship and support. You are all treasured and part of my heart.

Beyond this thesis, but well within my heart, are people who have one way or another contributed to me fulfilling this piece of work. Professor Adam Young, it has been a true blessing that our paths crossed. Thank you for the wonderful supervision for my research degree in the UK and for consolidating my desire to pursue an academic path. You were one of the first to believe in me. I thank you and love you deeply for this.

Allow me to go further back, to the root of everything I have done to date and to thank my parents for their unconditional love and endless support; for making it all possible for me. Papa and mama, Panikos and Maria, words are truly not enough. Thank you.

I wish to finish by thanking my immediate family, starting with my husband, my 'rock' in life, George. George thank you for being by my side, through-

out the good and the bad and for believing in me. Without you, none of this would have been possible. Last, but certainly not least, I wish above all, to devote this book to my five little (for now) musketeers: Alex, Manos, Evagelia, Orestis and Danae. I set off with the two of you and as I continued on my journey along, came the other three! Thank you for putting up with mummy's long work hours and for making you 'miss mummy' whilst away for work. I love you beyond words and want you to always remember, that where there is a will, there is a way.

